DK1748790T3 - Multiplasmidsystem til produktion af influenzavirus - Google Patents

Multiplasmidsystem til produktion af influenzavirus Download PDF

Info

Publication number
DK1748790T3
DK1748790T3 DK05750661.0T DK05750661T DK1748790T3 DK 1748790 T3 DK1748790 T3 DK 1748790T3 DK 05750661 T DK05750661 T DK 05750661T DK 1748790 T3 DK1748790 T3 DK 1748790T3
Authority
DK
Denmark
Prior art keywords
virus
influenza
cells
viruses
mdv
Prior art date
Application number
DK05750661.0T
Other languages
English (en)
Inventor
Hong Jin
Bin Lu
George Kemble
Erich Hoffmann
Gregory Duke
Zhongying Chen
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Application granted granted Critical
Publication of DK1748790T3 publication Critical patent/DK1748790T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (15)

1. Fremgangsmåde til forøgelse af replikationen af et reassortant influenzavirus, hvilken fremgangsmåde omfatter trinene: i) sammenligning af aminosyresekvensen for det reassortante influenzavirus med aminosyresekvensen for et andet influenzavirus, hvilket andet influenzavirus vokser i embryonerede æg; ii) ændring af en eller flere aminosyrer i et H3N2-HA-polypeptid i det reassortante virus, så det matcher sekvensen for det andet influenzavirus, som omfatter substituering efter behov af HA-H3-aminosyrerester, forudsat at position 183 er en leucin og position 226 er en alanin, til derved frembringelse af et ændret reassortant virus; og iii) dyrkning af det ændrede reassortante virus i æg, hvor replikationen af det ændrede reassortante virus er forøget med mindst 10 % sammenlignet med replikation af uændret reassortant virus.
2. Fremgangsmåde ifølge krav 1, hvor det ændrede reassortante virus er et 6:2-reassortant virus.
3. Fremgangsmåde ifølge krav 1, hvor det ændrede reassortante virus er et 7:1-reassortant virus.
4. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 3, hvor det ændrede reassortante virus er svækket, temperaturfølsomt og/eller kuldetilpasset.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor det ændrede reassortante virus omfatter et polynukleotid fra et influenza A/Ann Arbor/6/60-stamme virus.
6. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor det ændrede reassortante virus omfatter et polynukleotid fra et influenza B/Ann Arbor/l/66-stamme virus.
7. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 6, hvor replikationen af det ændrede reassortante influenzavirus er forøget med mindst 20 % sammenlignet med replikation af uændret reassortant virus.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 6, hvor replikationen af det ændrede reassortante influenzavirus er forøget med mindst 40 % sammenlignet med replikation af uændret reassortant virus.
9. Replikationsforbedret reassortant influenzavirus, der omfatter et H3N2-HA-protein, som omfatter en leucin i position 183 og en alanin i position 226.
10. Replikationsforbedret reassortant influenzavirus ifølge krav 9, som er et 6:2-reassortant virus.
11. Replikationsforbedret reassortant influenzavirus ifølge krav 9, som er et 7:1-reassortant virus.
12. Replikationsforbedret reassortant influenzavirus ifølge et hvilket som helst af kravene 9 til 11, som er svækket, temperaturfølsomt og/eller kuldetilpasset.
13. Replikationsforbedret reassortant influenzavirus ifølge et hvilket som helst af kravene 9 til 12, som omfatter et polynukleotid fra et influenza A/Ann Arbor/6/60-stamme virus.
14. Replikationsforbedret reassortant influenzavirus ifølge et hvilket som helst af kravene 9 til 12, som omfatter et polynukleotid fra et influenza B/Ann Arbor/l/66-stamme virus.
15. Immunogen sammensætning, der omfatter det replikationsforbedrede reassortante influenzavirus ifølge et hvilket som helst af kravene 9 til 14.
DK05750661.0T 2004-05-24 2005-05-20 Multiplasmidsystem til produktion af influenzavirus DK1748790T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US57411704P 2004-05-24 2004-05-24
US57896204P 2004-06-12 2004-06-12
US63189204P 2004-12-01 2004-12-01
US64327805P 2005-01-13 2005-01-13
US65737205P 2005-03-02 2005-03-02
PCT/US2005/017734 WO2005115448A2 (en) 2004-05-24 2005-05-20 Multi plasmid system for the production of influenza virus

Publications (1)

Publication Number Publication Date
DK1748790T3 true DK1748790T3 (da) 2015-10-19

Family

ID=35457258

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05750661.0T DK1748790T3 (da) 2004-05-24 2005-05-20 Multiplasmidsystem til produktion af influenzavirus

Country Status (5)

Country Link
EP (3) EP1748790B1 (da)
DK (1) DK1748790T3 (da)
ES (1) ES2550007T3 (da)
HU (1) HUE025727T2 (da)
WO (1) WO2005115448A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
WO2003091401A2 (en) 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
JP4617300B2 (ja) 2003-02-25 2011-01-19 メディミューン，エルエルシー インフルエンザワクチン組成物を生成する方法
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
JP4771959B2 (ja) 2003-12-23 2011-09-14 メディミューン，エルエルシー インフルエンザウイルス作製のための多重プラスミド系
CA2626266C (en) * 2005-10-17 2015-09-08 Medimmune, Llc Multi plasmid system for the production of influenza virus
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
KR101586968B1 (ko) * 2006-08-09 2016-01-20 메디뮨 엘엘씨 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체
EP3431099B1 (en) 2007-03-30 2024-01-03 The Research Foundation for The State University of New York Attenuated viruses useful for vaccines
US8673613B2 (en) 2007-06-18 2014-03-18 Medimmune, Llc Influenza B viruses having alterations in the hemaglutinin polypeptide
SG172220A1 (en) 2008-12-16 2011-07-28 Baxter Int Production of influenza vaccines
AU2014229255B2 (en) 2013-03-13 2018-12-13 Novartis Ag Influenza B virus reassortment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1862404A (en) 1931-03-19 1932-06-07 Wade H Jayne Brush holder
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
US6090391A (en) 1996-02-23 2000-07-18 Aviron Recombinant tryptophan mutants of influenza
US6951754B2 (en) 2000-04-28 2005-10-04 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
CA2827114A1 (en) * 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
WO2003091401A2 (en) * 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
JP4771959B2 (ja) * 2003-12-23 2011-09-14 メディミューン，エルエルシー インフルエンザウイルス作製のための多重プラスミド系

Also Published As

Publication number Publication date
EP1748790B1 (en) 2015-07-15
WO2005115448A8 (en) 2006-06-15
WO2005115448A3 (en) 2006-12-07
EP2644696A1 (en) 2013-10-02
HUE025727T2 (en) 2016-04-28
EP2644696B1 (en) 2015-07-15
ES2550007T3 (es) 2015-11-03
EP2995678A1 (en) 2016-03-16
WO2005115448A2 (en) 2005-12-08
EP1748790A4 (en) 2009-04-29
EP1748790A2 (en) 2007-02-07

Similar Documents

Publication Publication Date Title
CA2482946C (en) Multi plasmid system for the production of influenza virus
CA2626266C (en) Multi plasmid system for the production of influenza virus
DK1748790T3 (da) Multiplasmidsystem til produktion af influenzavirus
US9238825B2 (en) Multi plasmid system for the production of influenza virus
US9255253B2 (en) Multi plasmid system for the production of influenza virus
JP2009511073A6 (ja) インフルエンザウイルス製造用マルチプラスミド系